The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Monitors ... surely they have sold a few in these terrible times.
Monitors are used in ICU and they are building ICU’s in public parks! So should be more than fine. Plus they will be needed for recovery as well, more than just one application. They give a full patient read out with great graphics.
Trek
With the surge of Coronavirus, elective surgery in hospitals has been cancelled across the world (except for life threatening conditions).
Will this have an impact here, in particular the results to be published in April and sales projections for the rest of the year?
Hi Trek, saw your tip on ARB and had a look and have now got involved. Cash and no debt is always a big plus.
It’s not a drop google showing down 1.4. I just tried to buy and was quoted 9.6 buy, 8.6 sell on ii. Thought I was going to get a few on the cheap then! Lol!
Trek
Yes really looking forward to it, got a big holding here albeit late to the party but it doesn’t matter as long as it goes up and I think they are teeing up a big release for US and RoW sales. I have been through RNS’s all way to Apr 2014 and can’t see that they have ever raised which is usually the market fear. It’s not their style, they run a tight ship, costs under control, revenues from sales and recurring remote monitoring revenues. Ebit positive and cash on books. Don’t get why it’s not 50p! Yet! DYOR
Trek
And as for US revenues, also see co website, great ppt presentations...
· US revenues up 47% (42% on a constant currency basis) to £0.9m (H1 2018: £0.6m)
· EBITDA loss reduced by 70% to £0.3m (H1 2018: loss £0.9m)
· Strong balance sheet to support growth strategy with cash balances at 31 July 2019 of £1.2m (31 January 2019: £1.7m), and no debt
Cash and NO DEBT, they will obviously have a credit facility for cheap money but with recurring revenues and sales through the roof they shouldn’t need it. With their market leading differentiated products this imo is a little gem!
Trek
Incase you missed it “Uniquely LiDCO will be the only western supplier of hemodynamic monitoring solutions that is manufacturing its product locally in China. This could be a key differentiator as the vast majority of the 22,000 hospitals in China can only procure domestically manufactured products. China is the second largest healthcare market in the world with a five-year compound annual growth rate by value of 17% compared with 4% in the United States1.”
US still big obviously we’ll find out soon, and note the press coverage, states are outbidding each other for medical equipment!
Trek
“Any idea of the running costs for each monitor per year? I think they have sold over 200 so far this year“
The unit costs are not published in the accounts but they cost much less to run than the revenue that the generate. This is compounded by the fact that the company has gone 0.3m ebitda positive and that is set to increase significantly. Imo.
Trek
Any idea of the running costs for each monitor per year? I think they have sold over 200 so far this year
“doubt company will remain independent for long”
Precisely who else puts two slides in a corporate presentation about M&A benchmarks. Plan here is max revenue from cv19 and sell for 7x revenue. Remember once the units are sold then in rolls the fixed rate fees for diagnostic and maintenance. All imo albeit pretty obvious!
Trek
Medical kit is flowing even in EU they have green lanes and even in Italy key factories are open. Check out DCTA last RNS, based in Milan. Don’t forget LID monitor remotely, staff don’t have to travel and this stuff is plug and play.
Trek
Do they realy make the best? They have limited stock and suppliers are in Singapore so can't get much out of there right now.
Demand for LIDCO’s monitors, particularly LIDCORapid will be surging on the back of COVID19 and not just in the U.K. Expect the shares to trike from here and doubt company will remain independent for long. They make the best kit.